Laureen DeBuono - 16 Dec 2024 Form 4 Insider Report for Rani Therapeutics Holdings, Inc. (RANI)

Role
Director
Signature
Svai Sanford. Attorney-in-Fact for Laureen DeBuono
Issuer symbol
RANI
Transactions as of
16 Dec 2024
Net transactions value
$0
Form type
4
Filing time
17 Dec 2024, 17:00:07 UTC
Previous filing
30 May 2024
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction RANI Stock Option (Right to Buy) Disposed to Issuer -101,276 -100% 0 16 Dec 2024 Class A Common Stock 101,276 $2.84 Direct F1
transaction RANI Stock Option (Right to Buy) Award +101,276 101,276 16 Dec 2024 Class A Common Stock 101,276 $4.11 Direct F1
transaction RANI Stock Option (Right to Buy) Disposed to Issuer -18,875 -100% 0 16 Dec 2024 Class A Common Stock 18,875 $2.84 Direct F2, F3
transaction RANI Stock Option (Right to Buy) Award +18,875 +16% 135,896 16 Dec 2024 Class A Common Stock 18,875 $9.44 Direct F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 On December 16, 2024, the exercise price of the stock options has been amended to increase the exercise price to $4.11 per share. There is no change to the expiration dates or the vesting schedule of the options.
F2 The shares subject to the option vested as follows: 1/3rd of the shares subject to the option vested on April 20, 2022; and 1/36th of the shares subject to the option vested monthly over the following two years.
F3 On December 16, 2024, the exercise price of the stock options has been amended to increase the exercise price to $9.44 per share. There is no change to the expiration dates or the vesting schedule of the options.